29.09.2023 | Insight

eHCPs across the globe participate in the T2D online conversation

By Alexandra Maria Chatziioannidou

In a recent study conducted by CREATION.co to determine the Top 50 Digital Opinion Leaders in type 2 diabetes (T2D) we gathered more than 320,000 English and Spanish language T2D social media posts globally. These were posted by more than 50,000 eHCPs between January 2022 and March 2023. 

eHCP conversation was detected in more than 170 countries, with the most mentions coming from the United States, United Kingdom, Spain, India and Mexico. Around 18% of the overall posts around T2D were coming from the United States alone. When combined with posts from the UK, those two countries accounted for almost a third of the total posts. 

On social media there are no country borders; eHCPs were seen freely communicating with their peers all around the globe and collaborating in real time through social media on a daily basis.

Comparing English and Spanish language conversations, while English was the most dominant language used by eHCPs in the study, 20% of posts were written in Spanish. CREATION.co identified conversation clusters between countries which speak the same language. For example, a number of the DOLs located in Spain had a greater level of influence into Latin America than DOLs in English speaking countries. This worked two ways as the posts from a DOL in Latin America were frequently engaged with by eHCPs in Spain.

Reviewing the themes in conversation from the top five posting countries certain trends and similarities were observed. In the US, the most frequently discussed topic was the treatment of T2D as eHCPs were particularly active talking about specific treatments for type two diabetes.

In the UK the volume of posts around treatment and the volume of posts around research were almost identical. eHCPs shared studies and clinical trial results, which linked T2D to other health issues and provided further insights into tackling the condition.

In Spain, eHCPs focused on discussing treatment options with their peers, sharing their opinions and experiences on certain medications. In India treatment options were also a large part of the conversation but eHCPs also regularly discussed patient lifestyle choices to  be adhered to or avoided.  

If you want to find out more about our T2D study please watch the webinar: The Top 50 Global Digital Opinion Leaders in T2D or contact CREATION.co.


View all articles >

Meet the Author

Alexandra Maria Chatziioannidou

As a Biological Sciences graduate, Alexandra is passionate about making an impact in the healthcare industry through creating actionable insights and telling stories with data from online healthcare conversations.

Alexandra loves spending quality time with friends and family, both in the UK and back home in Greece, on her holidays. She also enjoys exploring new places!

Suggested next

06.06.2022 | Article

Product Launch Tracker: HCPs excited by approvals for Eli Lilly, Novartis, Sanofi and Regeneron

Over the last month, HCPs discussed product approvals for the treatment of a variety...

By Paul Cranston and Tomi Shobande

02.11.2023 | Article

Product Launch Tracker: eHCPs had positive reaction to the approval of the Novavax COVID-19 vaccine.

Discover what new drug approvals HCPs are talking about

By Alexandra Maria Chatziioannidou

View all articles >